Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18778754 | 0.97 | DGAT1 (0.54) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| SCHEMBL7196086 | 0.87 | DGAT1 (0.50) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| SCHEMBL808799 | 0.84 | DGAT1 (0.74) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| SCHEMBL23091415 | 0.81 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| Iodide SCHEMBL10533676 | 0.81 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| Ammonia Solution, Strong SCHEMBL7639328 | 0.81 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4GAA | |
| SCHEMBL29084303 | 0.79 | ALDH1A1 (0.37) | DGAT1ALDH1A1GAATSHR | |
| SCHEMBL248324 | 0.79 | DGAT1 (0.35) | DGAT1ALDH1A1GAATSHR | |
| SCHEMBL5859056 | 0.79 | DGAT1 (0.59) | DGAT1ALDH1A1ELANEKCNN4SRC | |
| SCHEMBL1010735 | 0.77 | DGAT1 (0.56) | DGAT1ALDH1A1ELANEKCNN4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | claimed |
| US-H2219-H1 | Method for coating small particles | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-07-01 | — | — | US | claimed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2025-12-23 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5110869-A | Block polymerization, endcapping, coupling, chain extension | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| US-4983679-A | ENDCAPPING, COUPLING, CHAIN EXTENSION OF POLYMERS | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0272285-A4 | ACYLATION AND SULFONATION OF SILYLKETENE ACETALS. | DU PONT (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0272285-A1 | ACYLATION AND SULFONATION OF SILYLKETENE ACETALS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-06-29 | — | — | EP | disclosed |
| WO-1987007265-A1 | ACYLATION AND SULFONATION OF SILYLKETENE ACETALS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-12-03 | — | — | WO | disclosed |
| US-4626543-A | PARTICULARY MOTHS | SHELL OIL COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987574-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | DGAT1 2022/4885ALDH1A1 4145/4885ELANE 1770/4885 |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | DGAT1 536/4885ALDH1A1 3425/4885ELANE 2883/4885 |
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | DGAT1 2885/4885ALDH1A1 2737/4885ELANE 4074/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | DGAT1 985/4885ALDH1A1 3116/4885ELANE 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.